Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Common Equity (2023 - 2025)

Historic Common Equity for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $180.5 million.

  • Contineum Therapeutics' Common Equity fell 1415.51% to $180.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.5 million, marking a year-over-year decrease of 1415.51%. This contributed to the annual value of $198.1 million for FY2024, which is 39154.79% up from last year.
  • Per Contineum Therapeutics' latest filing, its Common Equity stood at $180.5 million for Q3 2025, which was down 1415.51% from $171.4 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Common Equity ranged from a high of $217.5 million in Q2 2024 and a low of -$75.6 million during Q1 2024
  • For the 3-year period, Contineum Therapeutics' Common Equity averaged around $127.4 million, with its median value being $182.6 million (2025).
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 39154.79% in 2024, then crashed by 2120.11% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Common Equity (Quarter) stood at -$67.9 million in 2023, then surged by 391.55% to $198.1 million in 2024, then decreased by 8.88% to $180.5 million in 2025.
  • Its last three reported values are $180.5 million in Q3 2025, $171.4 million for Q2 2025, and $184.8 million during Q1 2025.